ArticleBMC cancer2017
MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.Journal of ovarian research · 2020Pooled it
- Overexpression of human interleukin 6 in NaCl inducible bacterial system and its characterization.Applied biochemistry and biotechnology · 2026Article
- Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026Article
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.Journal of advanced research · 2026Review
- Identification of serum peptide biomarkers for cholangiocarcinoma diagnosis and staging via MALDI-TOF MS and LC-MS/MS.British journal of cancer · 2026Article
- Early Diagnosis of Acute Kidney Injury in Liver Transplant Patients by an Untargeted Metabolomic Approach.Analytical science advances · 2025Article
- Mass spectrometry-based serum peptidomic profiling reveals potential biomarker for canine hepatozoonosis.Scientific reports · 2025Article
- The Fish Collagen Supplementation and Proteomic Features in Healthy Women-A Crossover Study.Nutrients · 2025Article
- Serum peptide biomarkers by MALDI-TOF MS coupled with machine learning for diagnosis and classification of hepato-pancreato-biliary cancers.Scientific reports · 2025Article
- Identification of peptidome-based biomarkers of cassava mosaic disease resistance in different cassava varieties.Scientific reports · 2025Article
- Proteomic analysis reveals potential biomarker candidates in serous ovarian tumors - a preliminary study.Contemporary oncology (Poznan, Poland) · 2025Article
- Article
- Evaluation of Serum Proteome Sample Preparation Methods to Support Clinical Proteomics Applications.Journal of the American Society for Mass Spectrometry · 2024Article
- Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence.International journal of molecular sciences · 2023Article
- Changes in Serum Protein-Peptide Patterns in Atopic Children Allergic to Plant Storage Proteins.International journal of molecular sciences · 2023Article
- Utilizing MALDI-TOF MS and LC-MS/MS to access serum peptidome-based biomarkers in canine oral tumors.Scientific reports · 2022Article
- Review
- Applications of MALDI-MS/MS-Based Proteomics in Biomedical Research.Molecules (Basel, Switzerland) · 2022Review
- Maternal serum proteomic profiles of pregnant women with type 1 diabetes.Scientific reports · 2022Article
- Identification of Endogenous Peptides in Nasal Swab Transport Media used in MALDI-TOF-MS Based COVID-19 Screening.ACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to high mortality and lack of efficient screening, new tools for ovarian cancer (OC) diagnosis are urgently needed. To broaden the knowledge on the pathological processes that occur during ovarian cancer tumorigenesis, protein-peptide profiling was proposed.
methodsSerum proteomic patterns in samples from OC patients were obtained using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). Eighty nine serum samples (44 ovarian cancer and 45 healthy controls) were pretreated using solid-phase extraction method. Next, a classification model with the most discriminative factors was identified using chemometric algorithms. Finally, the results were verified by external validation on an independent test set of samples.
resultsMain outcome of this study was an identification of potential OC biomarkers by applying liquid chromatography coupled with tandem mass spectrometry. Application of this novel strategy enabled the identification of four potential OC serum biomarkers (complement C3, kininogen-1, inter-alpha-trypsin inhibitor heavy chain H4, and transthyretin). The role of these proteins was discussed in relation to OC pathomechanism.
conclusionsThe study results may contribute to the development of clinically useful multi-component diagnostic tools in OC. In addition, identifying a novel panel of discriminative proteins could provide a new insight into complex signaling and functional networks associated with this multifactorial disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.